Trade Setup Buy Target $5.04 Sell Target $6.03 ContraFect Corporation, a clinical-stage biotechnology company, focuses on the discovery and development of therapeutic protein and antibody products for the treatment of life-threatening and drug-resistant infectious diseases in the United States. Its lead product candidates consist of CF-301, an investigational novel lysin, which is in Phase III […]
Read MoreTrade Setup Novan, Inc., a clinical development-stage biotechnology company, provides nitric oxide-based therapies to treat dermatological and oncovirus-mediated diseases. Its clinical stage dermatology drug candidates include SB204, a topical monotherapy for the treatment of acne vulgaris; SB206, a topical anti-viral gel for the treatment of viral skin infections; SB208, a topical broad-spectrum anti-fungal gel for […]
Read MoreTrade Setup Jaguar Health, Inc., a commercial stage pharmaceuticals company, focuses on developing prescription medicines for people and animals with GI distress, specifically chronic, debilitating diarrhea. It operates through two reportable segments, Human Health and Animal Health. The company, through its subsidiary, Napo Pharmaceuticals, Inc., focuses on developing and commercializing proprietary plant-based human gastrointestinal pharmaceuticals […]
Read MoreBuy Price: $2.20 or better Sell Price: TradersPro Sell Signal Hudson Technologies, Inc. a refrigerant services company, provides solutions to recurring problems within the refrigeration industry primarily in the United States. The company’s products and services include refrigerant and industrial gas sales; refrigerant management services consisting primarily of reclamation of refrigerants, re-usable cylinder refurbishment, and […]
Read MorePlus, Virgin Galactic shares are up after a successful spaceflight this weekend, FirstGroup is facing a shareholder rebellion over its plans to sell its iconic yellow school bus business, and Beyond Meat got an analyst upgrade.
Read MoreOver the last couple of weeks, the market has been largely range-bound, with an increasing level of volatility that has been making stocks pretty choppy. I think the shift in the uncertainty of which that volatility is a reflection is interesting; the ongoing health crisis remains a part of it, but most of the commentary […]
Read More